help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Debieve, F.
Right arrow Articles by Thomas, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debieve, F.
Right arrow Articles by Thomas, K.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 270-274
Copyright © 2000 by The Endocrine Society


Original Studies

Gonadotropins, Prolactin, Inhibin A, Inhibin B, and Activin A in Human Fetal Serum from Midpregnancy and Term Pregnancy

F. Debieve1, S. Beerlandt, C. Hubinont and K. Thomas

Department of Obstetrics and Gynecological Endocrinology, Université Catholique de Louvain, B-1200 Brussels, Belgium

Address all correspondence and requests for reprints to: Frédéric Debieve, M.D., Physiology of Human Reproduction Research Unit, Department of Obstetrics and Gynecologic Endocrinology, Faculty of Medicine, UCL 5330, Avenue Em. Mounier 53, B-1200 Brussels, Belgium. E-mail: debieve{at}obst.ucl.ac.be

Using specific enzyme-linked immunosorbent assays we measured inhibin A, inhibin B, and activin A in relation to LH, FSH, and PRL in normal human fetal midpregnancy serum obtained by in utero cord venipuncture (n = 25) and compared these results to those in fetal serum from term pregnancies (n = 23). We also tested serum from fetuses with intrauterine growth retardation (n = 6) or trisomy 21 (n = 6). We found no measurable inhibin A, except in three midpregnancy males (3 of 14). Inhibin B, however, was detected in midpregnancy male fetuses (167 ± 67 pg/mL) and was higher than that in females (16 ± 12 pg/mL). It was present in male term fetuses (125 ± 32 pg/mL), but not in females. The activin A levels did not significantly differ between term and midpregnancy males and females.

LH and FSH were detected in midpregnancy male fetuses (4.4 ± 3.3 and 0.77 ± 0.49 mIU/mL, respectively), with higher levels in females (33.0 ± 23.2 and 54.4 ± 27.7 mIU/mL, respectively), and were suppressed at term. PRL did not exhibit sexual difference, but showed a higher level at term (322.4 ± 113.8 ng/mL) than at midpregnancy (33.0 ± 26.1 ng/mL). Comparison of inhibin B with FSH levels showed correlation coefficients of -0.565 at midpregnancy vs. +0.445 at term. Serum from fetuses with intrauterine growth retardation or trisomy 21 did not show any different hormonal profiles.

These data suggest that inhibin B is probably an additional factor in FSH inhibition at midpregnancy, whereas activin A is not associated with any change in the different studied populations. We speculate that inhibin A could be a method to detect maternal blood contamination in cord venipuncture.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
S. Luisi, P. Florio, F. M. Reis, and F. Petraglia
Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy
Hum. Reprod. Update, March 1, 2005; 11(2): 123 - 135.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Fleenor, J. Oden, P. A. Kelly, S. Mohan, S. Alliouachene, M. Pende, S. Wentz, J. Kerr, and M. Freemark
Roles of the Lactogens and Somatogens in Perinatal and Postnatal Metabolism and Growth: Studies of a Novel Mouse Model Combining Lactogen Resistance and Growth Hormone Deficiency
Endocrinology, January 1, 2005; 146(1): 103 - 112.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Rubinek, M. Hadani, G. Barkai, S. Melmed, and I. Shimon
Prolactin (PRL)-Releasing Peptide Stimulates PRL Secretion from Human Fetal Pituitary Cultures and Growth Hormone Release from Cultured Pituitary Adenomas
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2826 - 2830.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Freemark, D. Fleenor, P. Driscoll, N. Binart, and P. A. Kelly
Body Weight and Fat Deposition in Prolactin Receptor-Deficient Mice
Endocrinology, February 1, 2001; 142(2): 532 - 537.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society